Details

Autor(en) / Beteiligte

• Gladding, Patrick A
• Cooper, Maxine
• Young, Renee
• Loader, Suzanne
• Smith, Kevin
• Zarate, Erica
• Green, Saras
• Villas Boas, Silas G
• Shepherd, Phillip
• Kakadiya, Purvi
• Thorstensen, Eric
• Keven, Christine
• Coe, Margaret
• Jüllig, Mia
• Zhang, Edmond
• Schlegel, Todd T

Titel

Metabolomics and a Breath Sensor Identify Acetone as a Biomarker for Heart Failure

Ist Teil von

• Biomolecules (Basel, Switzerland), 2023-01, Vol.13 (1), p.13

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Multi-omics delivers more biological insight than targeted investigations. We applied multi-omics to patients with heart failure with reduced ejection fraction (HFrEF). 46 patients with HFrEF and 20 controls underwent metabolomic profiling, including liquid/gas chromatography mass spectrometry (LC-MS/GC-MS) and solid-phase microextraction (SPME) volatilomics in plasma and urine. HFrEF was defined using left ventricular global longitudinal strain, ejection fraction and NTproBNP. A consumer breath acetone (BrACE) sensor validated results in n = 73. 28 metabolites were identified by GCMS, 35 by LCMS and 4 volatiles by SPME in plasma and urine. Alanine, aspartate and glutamate, citric acid cycle, arginine biosynthesis, glyoxylate and dicarboxylate metabolism were altered in HFrEF. Plasma acetone correlated with NT-proBNP (r = 0.59, 95% CI 0.4 to 0.7), 2-oxovaleric and cis-aconitic acid, involved with ketone metabolism and mitochondrial energetics. BrACE > 1.5 ppm discriminated HF from other cardiac pathology (AUC 0.8, 95% CI 0.61 to 0.92, < 0.0001). Breath acetone discriminated HFrEF from other cardiac pathology using a consumer sensor, but was not cardiac specific.